Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

26th May 2022

Portfolio

This post references, or is about Harpoon. Find out more by clicking below

San Francisco, USA

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article